Drug Trial Radar · NCT07709494
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Jul 13, 2026
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Revagenix, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult healthy participants and non-cystic fibrosis bronchiectasis (NCFB) patients with P. aeruginosa, respectively. Phase 1a (Part A) will evaluate single doses of inhaled Rev-56 in adult healthy participants and includes up to 5 cohorts. Eligible participants will be randomized to active treatment or placebo in a 3:1 randomization scheme. Phase 1b (Part B) will evaluate the safety, tolerability, microbiological response, and pharmacokinetics of multiple doses of inhaled Rev-56 in NCFB patients with P. aeruginosa and includes 2 cohorts evaluating once daily dosing and twice daily dosing, respectively. Eligible participants will be randomized to active treatment or placebo in a 2:1 randomization scheme.
Conditions
- Healthy Participants
- Non-cystic Fibrosis Bronchiectasis
Interventions
Rev-56 for InhalationCombination product
administered by inhalation via an investigational nebulizer device
Placebo: Normal salineDrug
administered by inhalation via an investigational nebulizer device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (AEs)Time frame: 21 days (healthy participants) or 28 days (NCFB patients with P. aeruginosa)
- Number of participants with clinically significant abnormalities in lab parameters, vital signs, respiratory function, and ECG parameters graded by FDA Toxicity Grading Scale (for healthy participants) and DAIDS Toxicity Tables (for NCFB patients)Time frame: 21 days (healthy participants) or 28 days (NCFB patients with P. aeruginosa)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Syneos Health Miami
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.